SCHEMBL2085996

SCHEMBL2085996

Cc1ccc(C(C)NC(CCCN)Cc2nc3ccccc3[nH]2)nc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 1/20 0.42
KMT2A Q03164 3/20 0.41
MAPK1 P28482 2/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
MEN1 O00255 1/20 0.41
TP53 P04637 1/20 0.41
CYP3A4 P08684 1/20 0.41
SMN1; SMN2 Q16637 7/20 0.40
RAB9A P51151 6/20 0.40
NPC1 O15118 5/20 0.40
POLB P06746 2/20 0.39
ALPL P05186 3/20 0.39
ALPI P09923 2/20 0.39
MAPT P10636 2/20 0.39
ALPG P10696 2/20 0.39
HTT P42858 2/20 0.39
LMNA P02545 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2082170 0.85 CXCR4 (0.46) CXCR4KMT2AMAPK1CYP2D6CYP2C9
SCHEMBL2083640 0.75 CXCR4 (0.52) CXCR4MAPK1RAB9ANPC1POLB
SCHEMBL12935343 0.73 CXCR4 (0.76) CXCR4CYP2D6SMN1; SMN2RAB9ANPC1
SCHEMBL2083756 0.73 CXCR4 (0.53) CXCR4
SCHEMBL2084688 0.70 CXCR4 (0.46) CXCR4KMT2AMAPK1CYP2D6CYP2C9
SCHEMBL2085384 0.70 CXCR4 (0.43) CXCR4MAPK1CYP2D6CYP2C9CYP2C19
SCHEMBL2084301 0.67 CXCR4 (0.55) CXCR4KMT2A
SCHEMBL8025715 0.65 DDAH1 (0.61) KMT2AMAPK1CYP2D6CYP2C9CYP2C19
SCHEMBL30207649 0.65 DDAH1 (0.61) KMT2AMAPK1CYP2D6CYP2C9CYP2C19
SCHEMBL2084975 0.65 CXCR4 (0.53) CXCR4KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7863293-B2 CXCR4 chemokine receptor binding compounds GENZYME CORPORATION (US) 2011-01-04 US claimed
US-20080255197-A1 CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS ANORMED CORPORATION (CA) 2008-10-16 US claimed
US-7291631-B2 CXCR4 chemokine receptor binding compounds GENZYME CORPORATION (US) 2007-11-06 US claimed
US-7863293-B2 CXCR4 chemokine receptor binding compounds GENZYME CORPORATION (US) 2011-01-04 US disclosed
US-20080255197-A1 CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS ANORMED CORPORATION (CA) 2008-10-16 US disclosed
US-7291631-B2 CXCR4 chemokine receptor binding compounds GENZYME CORPORATION (US) 2007-11-06 US disclosed
US-20040209921-A1 CXCR4 chemokine receptor binding comounds ANORMED CORPORATION (CA) 2004-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040209921-A1 CXCR4 chemokine receptor binding comounds CXCR4, CXCR1, CXCR3 CXCR4 1/4885KMT2A 4082/4885MAPK1 1365/4885
US-20080255197-A1 CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS CXCR4, CXCR1, CXCR3 CXCR4 1/4885KMT2A 2950/4885MAPK1 1259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.